SGHT (Sight Sciences) ROIC %: -298.39% (As of Mar. 2026)


SGHT Sight Sciences Inc SGHT
72 GF Score
Price $5.48
GF Value $4.49
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sight Sciences ROIC %?

Sight Sciences SGHT -0.40% 72 ROIC % is -298.39% as of Mar. 2026. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.49 (Modestly Overvalued). The stock has 3 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Sight Sciences's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was -298.39%.

As of today (2026-06-25), Sight Sciences's WACC % is 26.03%. Sight Sciences's ROIC % is -220.27% (calculated using TTM income statement data). Sight Sciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Sight Sciences  (NAS:SGHT) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Sight Sciences's WACC % is 26.03%. Sight Sciences's ROIC % is -220.27% (calculated using TTM income statement data). Sight Sciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Sight Sciences ROIC % Related Terms


Sight Sciences ROIC % Historical Data

* Premium members only.

The historical data trend for Sight Sciences's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sight Sciences ROIC % Chart

Sight Sciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial -538.19 -539.29 -271.23 -247.60 -205.63

Sight Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -349.82 -324.14 -188.99 -77.92 -298.39

SGHT vs QSI, TMCI, SI: ROIC % Comparison

For the Medical Devices subindustry, Sight Sciences's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sight Sciences ROIC % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's ROIC % distribution charts can be found below:

* The bar in red indicates where Sight Sciences's ROIC % falls into.


SGHT
72GF Score
Sight Sciences Inc SGHT
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sight Sciences ROIC % Calculation

Sight Sciences's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-37.099 * ( 1 - 0% )/( (17.227 + 18.857)/ 2 )
=-37.099/18.042
=-205.63 %

where

Sight Sciences's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-49.652 * ( 1 - 0% )/( (18.857 + 14.423)/ 2 )
=-49.652/16.64
=-298.39 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -298.39% mean?
Sight Sciences (SGHT) has a ROIC % of -298.39% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Sight Sciences and its competitors.
Is Sight Sciences' ROIC % too high?
Sight Sciences' current ROIC % is -298.39%. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' ROIC % compare to QSI and TMCI?
Sight Sciences' ROIC % of -298.39% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROIC % is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Medical Devices & Instruments company?
The median ROIC % among Medical Devices & Instruments companies is 1.27, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median ROIC % is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current ROIC % is -298.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.49, compared to a current price of $5.48 — trading 22% above its estimated fair value. The current ROIC % is -298.39%. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Sight Sciences (SGHT), the current ROIC % is -298.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sight Sciences (SGHT) Overvalued in 2026?

Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued. The current stock price of $5.48 is trading 22% above its estimated GF Value™ of $4.49. GuruFocus considers Sight Sciences to be Modestly Overvalued.

Key valuation signals for SGHT:

  • ROIC %: -298.39%
  • GF Value™: $4.49 vs. price of $5.48 (22% above fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sight Sciences Business Description

Address 4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score

Get the complete analysis for SGHT

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.48
Price
$4.49
GF Value